We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enteric Nervous System in Parkinson's Disease (ENTEROPARK)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00491062
First Posted: June 25, 2007
Last Update Posted: November 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nantes University Hospital
June 22, 2007
June 25, 2007
November 16, 2010
June 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00491062 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Enteric Nervous System in Parkinson's Disease
Analysis of Dopamine Neuronal Cell Loss Within the Enteric Nervous System in Parkinson's Disease
The "core" of the neuronal lesions in Parkinson's disease (PD) is the progressive degeneration of dopamine neurons in the substantia nigra. A significant loss of dopamine neurons and the presence of Lewy bodies (a pathological hallmark in PD) in enteric neurons have also been reported in that disease. These lesions may explain the frequent gastro-intestinal dysfunction observed in PD patients. Alterations of other neuronal populations within the enteric nervous system (ENS) as well as the mechanisms responsible for these lesions (type of cell death, alteration of neuromediators gene expression) remain to be identified. The aim of the study is to demonstrate that alterations of the human ENS in PD can be evidenced by bowel biopsies and to determine whether they are correlated to the severity of motor disability and to gastrointestinal dysfunction.
Not Provided
Interventional
Not Provided
Intervention Model: Parallel Assignment
Parkinson's Disease
Procedure: Biopsies
  • Active Comparator: Control
    Intervention: Procedure: Biopsies
  • Experimental: Parkinson stade 1
    Intervention: Procedure: Biopsies
  • Experimental: Parkinson stade2
    Intervention: Procedure: Biopsies
  • Experimental: Parkinson stade 3
    Intervention: Procedure: Biopsies
Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N'Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, Derkinderen P. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One. 2010 Sep 14;5(9):e12728. doi: 10.1371/journal.pone.0012728.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
November 2009
Not Provided

Inclusion Criteria:

  • Parkinson's disease patients at 3 different stages:

    • Early PD (before L-DOPA-induced complication);
    • Patients with L-DOPA-induced complication;
    • Patients with balance impairment or cognitive decline.
  • Controls: patient at risk of colic cancer for whom a coloscopy is required.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00491062
06-5-I
No
Not Provided
Not Provided
Not Provided
Nantes University Hospital
Not Provided
Study Director: DAMIER Philippe CHU Nantes
Nantes University Hospital
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP